Detailed Narrative
Q1 FY27 Financial Performance Overview
Aarti Drugs reported a strong start to FY27 with consolidated revenue reaching INR703.6 crores, marking a 19% year-on-year growth. This performance was primarily driven by improved API realizations and volume growth across key products. EBITDA for the quarter stood at INR96.9 crores, a 30% increase year-on-year, leading to an EBITDA margin expansion of 120 basis points to 13.8%. Profit Before Tax (PBT) also saw a significant rise of 35% year-on-year to INR69.2 crores, with PBT margin at 9.9%.
Operating Environment and Market Dynamics
The first quarter of FY27 was influenced by a dynamic global landscape, including geopolitical developments in West Asia, which impacted international trade, logistics, and supply chains. This led to elevated freight costs and increased raw material price volatility. However, these disruptions also created a favorable pricing environment for several API products, resulting in upward price movements and better realizations for the company. Management noted that customers are increasingly prioritizing supply security and long-term partnerships, areas where Aarti Drugs has built strong capabilities.
Manufacturing and Capacity Expansion Initiatives
The company's manufacturing facilities operated stably without production disruptions, material shortages, or supply interruptions. The Sayakha facility continued its ramp-up, operating at nearly 65% utilization in Q1 FY27, strengthening backward integration for the antidiabetic segment. Additionally, the brownfield expansion at the Baddi facility is progressing as planned, expected to nearly double the oral solid dosage manufacturing capacity. These investments are aimed at enhancing competitiveness and supporting long-term growth.
Metformin Expansion and USFDA Market Strategy
Aarti Drugs is significantly expanding its Metformin capacity from 1,400 tons per month to 2,200 tons per month at its Sarigam facility. A dedicated USFDA-compliant capacity of 500-550 tons per month is being added, with the new capacity expected to be ready in 10-12 months, after which the company plans to file for USFDA inspection. This strategic move aims to tap into the large US and European markets, where USFDA approval is often a prerequisite for suppliers.
Salicylic Acid Business Challenges and Strategy Shift
The salicylic acid business faced challenges in Q1 FY27, with production kept very low at 67 tons due to equipment installation and efforts to improve effluent quality. The anti-dumping duty for salicylic acid has been delayed by approximately one year, impacting the product's profitability. In response, the company has commissioned a new plant for manufacturing salicylic acid derivatives, such as methyl salicylate, with a capacity of 350-400 tons per month, to achieve breakeven for the Tarapur location.
Margin and Volume Growth Outlook
Despite continued raw material price pressure, Aarti Drugs achieved EBITDA margin expansion, demonstrating resilience in its operating models. Management expressed confidence in achieving a 14% EBITDA margin and targeting 15% once the utilization of greenfield projects improves and the salicylic acid plant becomes profitable. The company is also poised for a 10-15% volume growth over the next two years, with captive consumption at the Sayakha plant expected to reach 80-90% by the December quarter, contributing an additional 1% to gross margins at peak levels.